Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Preclinical Study Finds Nafamostat Blocks SARS-CoV-2 Infection in Human Lung Cells

americanpharmaceuticalreviewAugust 24, 2020

Tag: Nafamostat , SARS-CoV-2 , COVID-19

PharmaSources Customer Service